tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

OmniAb Announces $30M Private Placement Agreement

Story Highlights
OmniAb Announces $30M Private Placement Agreement

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

An update from OmniAb ( (OABI) ) is now available.

On August 24, 2025, OmniAb, Inc. entered into a securities purchase agreement for a private placement of 21,254,106 shares of common stock, expecting to raise approximately $30 million. The proceeds are intended for working capital and general corporate purposes. The private placement is set to close on August 26, 2025, and is conducted in accordance with Nasdaq rules. The company will file a registration statement with the SEC for the resale of the shares, and the placement is exempt from registration under the Securities Act. Leerink Partners acted as the placement agent.

The most recent analyst rating on (OABI) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on OmniAb stock, see the OABI Stock Forecast page.

Spark’s Take on OABI Stock

According to Spark, TipRanks’ AI Analyst, OABI is a Neutral.

OmniAb’s overall stock score reflects significant financial challenges, particularly in profitability and revenue growth, despite a stable balance sheet and improving cash flow. Technical analysis provides mixed signals, while valuation remains unattractive due to ongoing losses. The earnings call highlights potential future growth through partnerships and technology launches, but these are not factored into the score due to weight redistribution.

To see Spark’s full report on OABI stock, click here.

More about OmniAb

OmniAb licenses cutting-edge discovery research technology to pharmaceutical and biotech companies and academic institutions, enabling the discovery of next-generation therapeutics. The company’s platform creates and screens diverse antibody repertoires, identifying optimal antibodies and other target-binding proteins for drug development. OmniAb’s technology includes computational antigen design, immunization methods, and high-throughput screening, offering integrated and customizable solutions to address industry challenges.

Average Trading Volume: 750,215

Technical Sentiment Signal: Sell

Current Market Cap: $227M

Learn more about OABI stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1